Since announcing the terms for its initial public offering (IPO) earlier in September, Foundation Medicine, Inc. has reportedly boosted its goal from $75 million to $77.4 million. The Cambridge, Massachusetts-based molecular diagnostics company will use the proceeds, in part, to increase its sales force and support ongoing and new clinical studies. The company’s molecular information platform provides physicians with actionable genomic information about their cancer patients, enabling optimized treatment and the development of targeted oncology treatments. In its amended Form S-1 filed with the Securities and Exchange Commission, the company indicated that it planned to offer 5 million shares at a price between $14 and $16 per share. It has also granted underwriters an option to purchase up to an additional 750,000 shares of common stock. See Renaissance Capital, September 12, 2013; GenomeWeb.com, September 23, 2013.